Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Leases (2019 - 2025)

BridgeBio Pharma's Current Leases history spans 7 years, with the latest figure at $6.2 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 37.42% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.2 million, a 37.42% increase, with the full-year FY2025 number at $6.2 million, up 37.42% from a year prior.
  • Current Leases hit $6.2 million in Q4 2025 for BridgeBio Pharma, up from $5.3 million in the prior quarter.
  • Over the last five years, Current Leases for BBIO hit a ceiling of $6.2 million in Q4 2025 and a floor of $3.7 million in Q1 2023.
  • Historically, Current Leases has averaged $4.5 million across 5 years, with a median of $4.5 million in 2021.
  • Biggest five-year swings in Current Leases: soared 51.67% in 2021 and later fell 25.58% in 2022.
  • Tracing BBIO's Current Leases over 5 years: stood at $4.9 million in 2021, then fell by 25.58% to $3.7 million in 2022, then grew by 12.33% to $4.1 million in 2023, then grew by 9.16% to $4.5 million in 2024, then surged by 37.42% to $6.2 million in 2025.
  • Business Quant data shows Current Leases for BBIO at $6.2 million in Q4 2025, $5.3 million in Q3 2025, and $4.8 million in Q2 2025.